PG
Prostatype genomics Stock: price and insider trades · Sweden
No insider purchase over the last 90 days. The latest, by Michael Häggman, was filed 10 Nov 2022.
Prostatype genomics: what insiders have been doing
Insider filings for Prostatype genomics are scarce in the Finansinspektionen feed, the latest one published on 10 November 2022. This page will fill in as new trades are disclosed. Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.
Insider Decl.
1
Thresholds
n/a
Buy Volume
€1,825
1 ops. · all time
Sell Volume
n/a
n/a
Financial data
· cache
Last declaration on 10 November 2022
Declarations1 total
- 10,000 shares@ SEK 1.99100.0% of flowAktieFI:csv-d64cf62337b207b6d101Canonical exit: 8 Feb 2023 (T+90)
1 of 1 declaration
About Prostatype genomics
Prostatype Genomics is a company focused on developing genomic tests for prostate cancer. It is listed on the Stockholm Stock Exchange.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations